|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅰ / Ⅱ study of continuousnfusion troxacitabine in refractory acute myeloid leukemia 显示文摘 | Roboz GJ Giles FJ Ritchie EK | 2007 | J Clin Oncol2007，25，1： | 1 |
| 2 | TNF - α targeted therapeutic approaches in patients with hematologic malignancies 显示文摘 | Tsimberidou AM Giles FJ | 2002 | Expert Review of Anticancer Therapy2002，2，3： | 1 |
| 3 | Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes 显示文摘 | Aguayo A Kantarjian HM Estey EH Giles FJ Verstovsek S Manshouri T | 2002 | Cancer2002，95，9： | 1 |
| 4 | Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome显示文摘 | ROBOZ G J GILES FJ LIST A F | 2006 | Leukemia2006，20，6： | 1 |
| 5 | Phase Ⅰ/Ⅱ study of continuousinfusion troxacitabine in refractory acute myeloid leukemia显示文摘 | Roboz GJ Giles FJ Ritchie EK | 2007 | J Clin Oncol2007，25，1： | 1 |
| 6 | Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia显示文摘 | Estey EH Giles FJ Beran M | 2002 | Blood2002，99，： | 1 |
| 7 | Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leuke -mia and myelodysplastic syndrome显示文摘 | Roboz GJ Giles FJ List AF | 2006 | Leukemia2006，20，6： | 1 |
| 8 | Outcome with the hyper--CVAD regimens in lymphoblastie lymphoma显示文摘 | Thomas DA O'Bricn S Giles FJ | 2004 | Blood2004，104，6： | 1 |
| 9 | Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma显示文摘 | Thomas DA O′ Brien S Giles FJ | 2004 | Blood2004，104，6： | 1 |
| 10 | Phase I and pharmacokinetic study of DX-8951 f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia 显示文摘 | Giles FJ Cortes JE Thomas DA | 2002 | Clin Cancer Res2002，8，7： | 1 |
| 11 | Acute myeloid leukemia hematology显示文摘 | Giles FJ Keating A Goldstone AH | 2002 | Am Soc Hematol Educ Program2002，1，： | 1 |
| 12 | Phase 1 study of low-dose prolonged exposure schedules of the hy- pomethylating agent 5-aza-2'-deoxycytidine(decitabine) in hematopoietic malignancies 显示文摘 | Issa JP Garciamanero G Giles FJ | 2004 | Blood2004，103，5： | 1 |
| 13 | Optimizing outcomes for patients with advanced disease in chronic mydogenous leukemia 显示文摘 | Giles FJ DeAngelo D J Baccarani M | 2008 | Semin Oncol2008，35，1： | 1 |
| 14 | The potential of amifostine from cytoprotectant to therapeutic agent显示文摘 | Santini V Giles FJ | 1999 | HaematoIogica1999，84，11： | 1 |
| 15 | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes显示文摘 | Giles FJ Stopeck AT Silverman LR | 2003 | Blood2003，102，3： | 1 |
| 16 | A phase III, ran- domized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomato- toxic ehemotherapy显示文摘 | Giles FJ Rodriguez R Weisdorf D | 2004 | Leuk Res2004，28，6： | 1 |
| 17 | Mammalian Target of rapamycin inhibition as therapy for hematologic malignancies显示文摘 | Panwalkar A Verstovsek S Giles FJ | 2004 | Cancer2004，100，4： | 1 |
| 18 | MK-0457,a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation 显示文摘 | Giles FJ Cortes J Jones D | 2007 | Blood2007，109，2： | 1 |
| 19 | The emerging role of angiogenesis inhibitors in hematologic malignancies显示文摘 | Giles FJ | 2002 | Oncology ( Huntingt )2002，16，54： | 1 |
| 20 | Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine(decitabine) in hematopoietic malignancies显示文摘 | Issa JP Garcia-Manero G Giles FJ | 2004 | Blood2004，103，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员